person · Reporting owner

Kauffman Michael

Disclosed activity across 6 companies

Tapewire entity: 37452
SEC CIK: 0001364719

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802	Director	June 13, 2019	June 14, 2019
KYNTRA BIO, INC.KYNB · Entity 7431	Director	June 12, 2026	June 17, 2026
Karyopharm Therapeutics Inc.KPTI · Entity 781	Director	February 28, 2022	March 02, 2022
Verastem, Inc.VSTM · Entity 5242	Director · President of Development	January 06, 2026	January 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INFINITY PHARMACEUTICALS, INC.

Report date June 13, 2019 · Filed June 14, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2029-06-12	Direct	30,000	Reported balance After 2019-06-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-13 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.

KYNTRA BIO, INC.

Report date June 12, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.13 · Expires 2036-06-11	Direct	7,000	Reported balance After 2026-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-12 · Grant · Acquired 7,000 · Balance 7,000 F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.

Karyopharm Therapeutics Inc.

Report date February 28, 2022 · Filed March 02, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	713,757	Ending reported balance After 2022-02-28 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-02-28 · Grant · Acquired 21,000 · Balance 719,983 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. Row 2 · 2022-02-28 · Sale · Disposed 6,226 · Balance 713,757 F2: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Common StockSEC Table I · non-derivative	IndirectBy Spouse	898,131	Reported balance After 2022-02-28 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2022-02-28 · Sale · Disposed 6,226 · Balance 898,131 F4: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person. F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.33 · Expires 2032-02-27	Direct	27,000	Reported balance After 2022-02-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-02-28 · Grant · Acquired 27,000 · Balance 27,000 F5: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

F2: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F5: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Verastem, Inc.

Report date January 06, 2026 · Filed January 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.88 · Expires 2036-01-06	Direct	200,000	Reported balance After 2026-01-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-06 · Grant · Acquired 200,000 · Balance 200,000 F1: The stock option vests 33.33% of the shares on the first anniversary of January 6, 2026 (the "Grant Date"), and an additional 8.33% will vest at the end of each successive three-month period following the first anniversary of the Grant Date until the third anniversary of the Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest) provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests 33.33% of the shares on the first anniversary of January 6, 2026 (the "Grant Date"), and an additional 8.33% will vest at the end of each successive three-month period following the first anniversary of the Grant Date until the third anniversary of the Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest) provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Adicet Bio, Inc.

Report date August 21, 2024 · Filed August 23, 2024

Section 16 reporting ended · disclosed 2024-08-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-11-16	Direct	0	Reported balance After 2024-08-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-08-21 · Disposition to issuer · Disposed 37,000 · Balance 0 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.39 · Expires 2031-11-16	Direct	37,000	Reported balance After 2024-08-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-08-21 · Grant · Acquired 37,000 · Balance 37,000 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2032-06-01	Direct	0	Reported balance After 2024-08-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-08-21 · Disposition to issuer · Disposed 18,500 · Balance 0 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: The shares subject to this option are fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2032-06-01	Direct	18,500	Reported balance After 2024-08-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-08-21 · Grant · Acquired 18,500 · Balance 18,500 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: The shares subject to this option are fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2033-05-31	Direct	0	Reported balance After 2024-08-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-08-21 · Disposition to issuer · Disposed 26,400 · Balance 0 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: The shares subject to this option are fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.20 · Expires 2033-05-31	Direct	26,400	Reported balance After 2024-08-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-08-21 · Grant · Acquired 26,400 · Balance 26,400 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: The shares subject to this option are fully vested and exercisable as of the date hereof.

Filing footnotes · ownership attribution and instrument terms

F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

F3: The shares subject to this option are fully vested and exercisable as of the date hereof.

Kezar Life Sciences, Inc.

Report date May 11, 2026 · Filed May 11, 2026

Section 16 reporting ended · disclosed 2026-05-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-05-11 transaction · row 1 1 source row Row 1 · 2026-05-11 · Other · Disposed 6,369 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR Agreement with Broadridge Corporate Issuer Solutions, LLC, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.10 · Expires 2028-04-15	Direct	Reported balance After 2026-05-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-11 · Disposition to issuer · Disposed 389 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.40 · Expires 2033-06-14	Direct	Reported balance After 2026-05-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-11 · Disposition to issuer · Disposed 3,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2034-06-19	Direct	Reported balance After 2026-05-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2035-06-17	Direct	Reported balance After 2026-05-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2029-06-24	Direct	Reported balance After 2026-05-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-11 · Disposition to issuer · Disposed 889 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2030-06-23	Direct	Reported balance After 2026-05-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-05-11 · Disposition to issuer · Disposed 889 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2031-06-27	Direct	Reported balance After 2026-05-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-05-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2032-06-15	Direct	Reported balance After 2026-05-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-05-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement")

F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR Agreement with Broadridge Corporate Issuer Solutions, LLC, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.

F4: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 12, 2026 Filed Jun 17, 2026 23:40 UTC	KYNTRA BIO, INC. KYNB · Entity 7431	GrantStock Option (Right to Buy) · Derivative	7,000	$0.00 Strike: $7.13	$0.00	Disclosure SEC source: 0001364719-26-000004 · form4-06172026_110646.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (right to buy) · Derivative	2,600	$0.00 Strike: $22.80	$0.00	Disclosure SEC source: 0001364719-26-000002 · form4-05112026_040513.xml · derivative · entry 9 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires 2032-06-15 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (right to buy) · Derivative	2,600	$0.00 Strike: $22.80	$0.00	Disclosure SEC source: 0001364719-26-000002 · form4-05112026_040513.xml · derivative · entry 8 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires 2031-06-27 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (right to buy) · Derivative	889	$0.00 Strike: $22.80	$0.00	Disclosure SEC source: 0001364719-26-000002 · form4-05112026_040513.xml · derivative · entry 7 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 889 shares Expires 2030-06-23 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (right to buy) · Derivative	889	$0.00 Strike: $22.80	$0.00	Disclosure SEC source: 0001364719-26-000002 · form4-05112026_040513.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 889 shares Expires 2029-06-24 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $4.46	$0.00	Disclosure SEC source: 0001364719-26-000002 · form4-05112026_040513.xml · derivative · entry 5 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2035-06-17 F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $6.70	$0.00	Disclosure SEC source: 0001364719-26-000002 · form4-05112026_040513.xml · derivative · entry 4 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2034-06-19 F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (right to buy) · Derivative	3,500	$0.00 Strike: $26.40	$0.00	Disclosure SEC source: 0001364719-26-000002 · form4-05112026_040513.xml · derivative · entry 3 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2033-06-14 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (right to buy) · Derivative	389	$0.00 Strike: $59.10	$0.00	Disclosure SEC source: 0001364719-26-000002 · form4-05112026_040513.xml · derivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 389 shares Expires 2028-04-15 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	OtherCommon Stock	6,369	Not disclosed	Not disclosed	Disclosure SEC source: 0001364719-26-000002 · form4-05112026_040513.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") F2 · kind: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR Agreement with Broadridge Corporate Issuer Solutions, LLC, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time"). F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") Read SEC document
January 06, 2026 Filed Jan 8, 2026 21:01 UTC	Verastem, Inc. VSTM · Entity 5242	GrantStock Option (right to buy) · Derivative	200,000	$0.00 Strike: $6.88	$0.00	Disclosure SEC source: 0001104659-26-002117 · tm262491-1_4seq1.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · President of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2036-01-06 F1 · derivative.exercise_date: The stock option vests 33.33% of the shares on the first anniversary of January 6, 2026 (the "Grant Date"), and an additional 8.33% will vest at the end of each successive three-month period following the first anniversary of the Grant Date until the third anniversary of the Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest) provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document
November 21, 2025 Filed Nov 25, 2025 22:34 UTC	Verastem, Inc. VSTM · Entity 5242	SaleCommon Stock	8,550	$10.00	$85,500.00	Disclosure SEC source: 0001104659-25-116060 · tm2532206-3_4seq1.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,666 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.00 through $10.01, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document
June 18, 2025 Filed Jun 23, 2025 21:00 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $4.46	$0.00	Disclosure SEC source: 0001415889-25-017970 · form4-06232025_050612.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-06-17 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/18/2026, subject to Reporting Person continuing to provide service through such date. Read SEC document
June 04, 2025 Filed Jun 6, 2025 20:17 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	120,000	$0.00 Strike: $0.31	$0.00	Disclosure SEC source: 0001415889-25-015983 · form4-06062025_080643.xml · derivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-06-03 F2 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of four equal quarterly installments measured from the date of grant or the date of the next annual meeting of stockholders, subject to the reporting person's continued service at each applicable vest date. Read SEC document
June 04, 2025 Filed Jun 6, 2025 20:17 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	70,000	$0.00 Strike: $0.31	$0.00	Disclosure SEC source: 0001415889-25-015983 · form4-06062025_080643.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over three years from the date of grant, subject to the reporting person's continued service at each applicable vest date. Read SEC document
May 22, 2025 Filed May 27, 2025 21:44 UTC	Verastem, Inc. VSTM · Entity 5242	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $7.48	$0.00	Disclosure SEC source: 0001104659-25-053096 · tm2516118-4_4seq1.xml · derivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-05-22 F2 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document
May 22, 2025 Filed May 27, 2025 21:44 UTC	Verastem, Inc. VSTM · Entity 5242	GrantCommon Stock	8,333	$0.00	$0.00	Disclosure SEC source: 0001104659-25-053096 · tm2516118-4_4seq1.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,216 F1 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document
August 21, 2024 Filed Aug 23, 2024 20:05 UTC	Adicet Bio, Inc. ACET · Entity 6860	GrantStock Option (Right to Buy) · Derivative	26,400	$0.00 Strike: $5.20	$0.00	Disclosure SEC source: 0000950170-24-100173 · ownership.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
August 21, 2024 Filed Aug 23, 2024 20:05 UTC	Adicet Bio, Inc. ACET · Entity 6860	Disposition to issuerStock Option (Right to Buy) · Derivative	26,400	$0.00 Strike: $2.14	$0.00	Disclosure SEC source: 0000950170-24-100173 · ownership.xml · derivative · entry 5 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
August 21, 2024 Filed Aug 23, 2024 20:05 UTC	Adicet Bio, Inc. ACET · Entity 6860	GrantStock Option (Right to Buy) · Derivative	18,500	$0.00 Strike: $11.49	$0.00	Disclosure SEC source: 0000950170-24-100173 · ownership.xml · derivative · entry 4 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-01 F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
August 21, 2024 Filed Aug 23, 2024 20:05 UTC	Adicet Bio, Inc. ACET · Entity 6860	Disposition to issuerStock Option (Right to Buy) · Derivative	18,500	$0.00 Strike: $2.14	$0.00	Disclosure SEC source: 0000950170-24-100173 · ownership.xml · derivative · entry 3 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires 2032-06-01 F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
August 21, 2024 Filed Aug 23, 2024 20:05 UTC	Adicet Bio, Inc. ACET · Entity 6860	GrantStock Option (Right to Buy) · Derivative	37,000	$0.00 Strike: $9.39	$0.00	Disclosure SEC source: 0000950170-24-100173 · ownership.xml · derivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2031-11-16 F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document
August 21, 2024 Filed Aug 23, 2024 20:05 UTC	Adicet Bio, Inc. ACET · Entity 6860	Disposition to issuerStock Option (Right to Buy) · Derivative	37,000	$0.00 Strike: $2.14	$0.00	Disclosure SEC source: 0000950170-24-100173 · ownership.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,000 shares Expires 2031-11-16 F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document
June 20, 2024 Filed Jun 21, 2024 20:20 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $0.67	$0.00	Disclosure SEC source: 0001415889-24-017839 · form4-06212024_040609.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/20/2025, subject to Reporting Person continuing to provide service through such date. Read SEC document
June 18, 2024 Filed Jun 21, 2024 00:30 UTC	Verastem, Inc. VSTM · Entity 5242	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $3.27	$0.00	Disclosure SEC source: 0001104659-24-073606 · tm2417704-9_4seq1.xml · derivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-18 F2 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document
June 18, 2024 Filed Jun 21, 2024 00:30 UTC	Verastem, Inc. VSTM · Entity 5242	GrantCommon Stock	8,333	$0.00	$0.00	Disclosure SEC source: 0001104659-24-073606 · tm2417704-9_4seq1.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,883 F1 · shares: Restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:05 UTC	Adicet Bio, Inc. ACET · Entity 6860	GrantStock Option (Right to Buy) · Derivative	26,400	$0.00 Strike: $1.44	$0.00	Disclosure SEC source: 0000950170-24-070605 · ownership.xml · derivative · entry 3 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2034-06-04 F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:05 UTC	Adicet Bio, Inc. ACET · Entity 6860	SaleCommon Stock	5,900	$1.43	$8,437.00	Disclosure SEC source: 0000950170-24-070605 · ownership.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,900 Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:05 UTC	Adicet Bio, Inc. ACET · Entity 6860	GrantCommon Stock	5,900	$0.00	$0.00	Disclosure SEC source: 0000950170-24-070605 · ownership.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,800 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document
March 11, 2024 Filed Mar 13, 2024 22:07 UTC	Verastem, Inc. VSTM · Entity 5242	GrantStock Option (right to buy) · Derivative	16,078	Not disclosed Strike: $11.44	Not disclosed	Disclosure SEC source: 0001104659-24-034034 · tm248737-1_4seq1.xml · derivative · entry 9 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,078 Underlying: Common Stock · 16,078 shares Expires 2034-03-11 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 16,078 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F1 · derivative.exercise_date: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 16,078 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. Read SEC document
March 11, 2024 Filed Mar 13, 2024 22:07 UTC	Verastem, Inc. VSTM · Entity 5242	Disposition to issuerStock Option (right to buy) · Derivative	2,083	Not disclosed Strike: $49.92	Not disclosed	Disclosure SEC source: 0001104659-24-034034 · tm248737-1_4seq1.xml · derivative · entry 8 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2031-06-28 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 16,078 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F9 · derivative.exercise_date: The canceled stock option was granted on June 28, 2021 and provided for vesting in twelve equal month installments beginning on the on the last day of each month over a period from June 2021 to May 2022. Read SEC document
March 11, 2024 Filed Mar 13, 2024 22:07 UTC	Verastem, Inc. VSTM · Entity 5242	Disposition to issuerStock Option (right to buy) · Derivative	2,083	Not disclosed Strike: $21.24	Not disclosed	Disclosure SEC source: 0001104659-24-034034 · tm248737-1_4seq1.xml · derivative · entry 7 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2030-06-16 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 16,078 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F8 · derivative.exercise_date: The canceled stock option was granted on June 16, 2020 and provided for vesting in twelve equal monthly installments beginning on June 30, 2020 and ending on May 31, 2021. Read SEC document
March 11, 2024 Filed Mar 13, 2024 22:07 UTC	Verastem, Inc. VSTM · Entity 5242	Disposition to issuerStock Option (right to buy) · Derivative	2,083	Not disclosed Strike: $21.72	Not disclosed	Disclosure SEC source: 0001104659-24-034034 · tm248737-1_4seq1.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2029-06-21 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 16,078 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F7 · derivative.exercise_date: The canceled stock option was granted on June 21, 2019 and provided for vesting in twelve equal monthly installments beginning on July 21, 2019 and ending on June 21, 2020. Read SEC document
March 11, 2024 Filed Mar 13, 2024 22:07 UTC	Verastem, Inc. VSTM · Entity 5242	Disposition to issuerStock Option (right to buy) · Derivative	2,083	Not disclosed Strike: $67.08	Not disclosed	Disclosure SEC source: 0001104659-24-034034 · tm248737-1_4seq1.xml · derivative · entry 5 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2028-06-11 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 16,078 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F6 · derivative.exercise_date: The canceled stock option was granted on June 21, 2018 and provided for vesting in twelve equal monthly installments beginning on July 11, 2018 ending on June 11, 2019. Read SEC document
March 11, 2024 Filed Mar 13, 2024 22:07 UTC	Verastem, Inc. VSTM · Entity 5242	Disposition to issuerStock Option (right to buy) · Derivative	2,083	Not disclosed Strike: $25.08	Not disclosed	Disclosure SEC source: 0001104659-24-034034 · tm248737-1_4seq1.xml · derivative · entry 4 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2027-06-13 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 16,078 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F5 · derivative.exercise_date: The canceled stock option was granted on June 13, 2017 and provided for vesting in twelve monthly installments through June 13, 2018, with the first monthly installment vesting on July 13, 2017. Read SEC document
March 11, 2024 Filed Mar 13, 2024 22:07 UTC	Verastem, Inc. VSTM · Entity 5242	Disposition to issuerStock Option (right to buy) · Derivative	2,083	Not disclosed Strike: $16.44	Not disclosed	Disclosure SEC source: 0001104659-24-034034 · tm248737-1_4seq1.xml · derivative · entry 3 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2026-06-13 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 16,078 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F4 · derivative.exercise_date: The canceled stock option was granted on June 14, 2016 and provided for vesting in twelve monthly installments through June 14, 2017, with the first monthly installment vesting on July 14, 2016. Read SEC document
March 11, 2024 Filed Mar 13, 2024 22:07 UTC	Verastem, Inc. VSTM · Entity 5242	Disposition to issuerStock Option (right to buy) · Derivative	1,497	Not disclosed Strike: $95.88	Not disclosed	Disclosure SEC source: 0001104659-24-034034 · tm248737-1_4seq1.xml · derivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,497 shares Expires 2025-06-11 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 16,078 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F3 · derivative.exercise_date: The canceled stock option was granted on June 12, 2015 and provided for vesting in twelve monthly installments through June 12, 2016, with the first monthly installment vesting on July 12, 2015. Read SEC document
March 11, 2024 Filed Mar 13, 2024 22:07 UTC	Verastem, Inc. VSTM · Entity 5242	Disposition to issuerStock Option (right to buy) · Derivative	2,083	Not disclosed Strike: $120.84	Not disclosed	Disclosure SEC source: 0001104659-24-034034 · tm248737-1_4seq1.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2024-06-10 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 16,078 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F2 · derivative.exercise_date: The canceled stock option was granted on June 10, 2014 and provided for vesting in twelve equal monthly installments from June 10, 2014 until June 10, 2015. Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:07 UTC	Adicet Bio, Inc. ACET · Entity 6860	GrantStock Option (Right to Buy) · Derivative	26,400	$0.00 Strike: $2.14	$0.00	Disclosure SEC source: 0001209191-23-046095 · doc4.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:07 UTC	Adicet Bio, Inc. ACET · Entity 6860	Disposition to issuerStock Option (Right to Buy) · Derivative	26,400	$0.00 Strike: $5.20	$0.00	Disclosure SEC source: 0001209191-23-046095 · doc4.xml · derivative · entry 5 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:07 UTC	Adicet Bio, Inc. ACET · Entity 6860	GrantStock Option (Right to Buy) · Derivative	18,500	$0.00 Strike: $2.14	$0.00	Disclosure SEC source: 0001209191-23-046095 · doc4.xml · derivative · entry 4 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-01 F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:07 UTC	Adicet Bio, Inc. ACET · Entity 6860	Disposition to issuerStock Option (Right to Buy) · Derivative	18,500	$0.00 Strike: $11.49	$0.00	Disclosure SEC source: 0001209191-23-046095 · doc4.xml · derivative · entry 3 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires 2032-06-01 F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:07 UTC	Adicet Bio, Inc. ACET · Entity 6860	GrantStock Option (Right to Buy) · Derivative	37,000	$0.00 Strike: $2.14	$0.00	Disclosure SEC source: 0001209191-23-046095 · doc4.xml · derivative · entry 2 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2031-11-16 F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:07 UTC	Adicet Bio, Inc. ACET · Entity 6860	Disposition to issuerStock Option (Right to Buy) · Derivative	37,000	$0.00 Strike: $9.39	$0.00	Disclosure SEC source: 0001209191-23-046095 · doc4.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,000 shares Expires 2031-11-16 F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document
July 24, 2023 Filed Jul 26, 2023 21:04 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (Right to Buy) · Derivative	26,000	Not disclosed Strike: $2.28	Not disclosed	Disclosure SEC source: 0001209191-23-043439 · doc4.xml · derivative · entry 8 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2032-06-15 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
July 24, 2023 Filed Jul 26, 2023 21:04 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (Right to Buy) · Derivative	26,000	Not disclosed Strike: $4.80	Not disclosed	Disclosure SEC source: 0001209191-23-043439 · doc4.xml · derivative · entry 7 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2032-06-15 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
July 24, 2023 Filed Jul 26, 2023 21:04 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (Right to Buy) · Derivative	26,000	Not disclosed Strike: $2.28	Not disclosed	Disclosure SEC source: 0001209191-23-043439 · doc4.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2031-06-27 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
July 24, 2023 Filed Jul 26, 2023 21:04 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (Right to Buy) · Derivative	26,000	Not disclosed Strike: $5.59	Not disclosed	Disclosure SEC source: 0001209191-23-043439 · doc4.xml · derivative · entry 5 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2031-06-27 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
July 24, 2023 Filed Jul 26, 2023 21:04 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (Right to Buy) · Derivative	8,896	Not disclosed Strike: $2.28	Not disclosed	Disclosure SEC source: 0001209191-23-043439 · doc4.xml · derivative · entry 4 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,896 Underlying: Common Stock · 8,896 shares Expires 2030-06-23 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
July 24, 2023 Filed Jul 26, 2023 21:04 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (Right to Buy) · Derivative	8,896	Not disclosed Strike: $5.60	Not disclosed	Disclosure SEC source: 0001209191-23-043439 · doc4.xml · derivative · entry 3 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,896 shares Expires 2030-06-23 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.